Bimekizumab versus Adalimumab in Plaque Psoriasis

The interleukin-17A and interleukin-17F monoclonal antibody bimekizumab led to a higher incidence of clearance of psoriasis lesions than the anti-TNF drug adalimumab over a period of 16 weeks but was associated with oral candidiasis.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 385; no. 2; pp. 130 - 141
Main Authors Warren, Richard B, Blauvelt, Andrew, Bagel, Jerry, Papp, Kim A, Yamauchi, Paul, Armstrong, April, Langley, Richard G, Vanvoorden, Veerle, De Cuyper, Dirk, Cioffi, Christopher, Peterson, Luke, Cross, Nancy, Reich, Kristian
Format Journal Article
LanguageEnglish
Published Boston Massachusetts Medical Society 08.07.2021
Subjects
Adverse events
Candidiasis
Clinical trials
Cytokines
Dermatology
Diarrhea
Immunoglobulin A
Immunoglobulin G
Monoclonal antibodies
Pathogenesis
Patients
Psoriasis
Respiratory tract diseases
Rheumatology
Rheumatology General
Skin diseases
TNF inhibitors
Tumor necrosis factor-TNF
Europe
Online AccessGet full text

Cover

More Information
Summary:The interleukin-17A and interleukin-17F monoclonal antibody bimekizumab led to a higher incidence of clearance of psoriasis lesions than the anti-TNF drug adalimumab over a period of 16 weeks but was associated with oral candidiasis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-3
ObjectType-Feature-4
content type line 23
ObjectType-Undefined-2
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2102388